Format

Send to

Choose Destination
Toxicol Res. 2014 Sep;30(3):211-20. doi: 10.5487/TR.2014.30.3.211.

In Vitro Genotoxicity Assessment of a Novel Resveratrol Analogue, HS-1793.

Author information

1
Department of Microbiology, Dong-A University College of Medicine, Busan, Korea.
2
Department of Research Center, Dong Nam Institute of Radiological and Medical Sciences, Busan, Korea.

Abstract

Resveratrol has received considerable attention as a polyphenol with various biological effects such as anti-inflammatory, anti-oxidant, anti-mutagenic, anti-carcinogenic, and cardioprotective properties. As part of the overall safety assessment of HS-1793, a novel resveratrol analogue free from the restriction of metabolic instability and the high dose requirement of resveratrol, we assessed genotoxicity in three in vitro assays: a bacterial mutation assay, a comet assay, and a chromosomal aberration assay. In the bacterial reverse mutation assay, HS-1793 did not increase revertant colony numbers in S. typhimurium strains (TA98, TA100, TA1535 and TA1537) or an E. coli strain (WP2 uvrA) regardless of metabolic activation. HS-1793 showed no evidence of genotoxic activity such as DNA damage on L5178Y Tk(+/-) mouse lymphoma cells with or without the S9 mix in the in vitro comet assay. No statistically significant differences in the incidence of chromosomal aberrations following HS-1793 treatment was observed on Chinese hamster lung cells exposed with or without the S9 mix. These results provide additional evidence that HS-1793 is non-genotoxic at the dose tested in three standard tests and further supports the generally recognized as safe determination of HS-1793 during early drug development.

KEYWORDS:

Bacterial mutation assay; Chromosomal aberration assay; Comet assay; Genotoxicity; HS-1793; Resveratrol

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center